Does the media favor ACAD or CRVS?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for ACADIA Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Corvus Pharmaceuticals' score of -0.07 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CRVS or CELC?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is CRVS or CELC more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Celcuity N/A -350.78% -41.54%

Does the media refer more to CRVS or CELC?

In the previous week, Celcuity had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for Corvus Pharmaceuticals. Celcuity's average media sentiment score of 0.69 beat Corvus Pharmaceuticals' score of -0.07 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CRVS or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is CRVS or EWTX more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media refer more to CRVS or EWTX?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Corvus Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.50 beat Corvus Pharmaceuticals' score of -0.07 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, DYN or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is DYN or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer DYN or CRVS?

In the previous week, Dyne Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Dyne Therapeutics and 2 mentions for Corvus Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.27 beat Corvus Pharmaceuticals' score of -0.07 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ELVN or CRVS?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is ELVN or CRVS more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer ELVN or CRVS?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Enliven Therapeutics and 2 mentions for Corvus Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.54 beat Corvus Pharmaceuticals' score of -0.07 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Corvus Pharmaceuticals (CRVS) Competitors

$12.56 +0.01 (+0.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 -0.06 (-0.51%)

As of 09/18/2026 07:56 PM Eastern

Compare

CRVS vs. ACAD, CELC, EWTX, DYN, and ELVN

Should you buy Corvus Pharmaceuticals stock or one of its competitors? Corvus Pharmaceuticals's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), Edgewise Therapeutics (EWTX), Dyne Therapeutics (DYN), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

ACADIA Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for ACADIA Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.88 beat Corvus Pharmaceuticals' score of -0.07 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Corvus Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals currently has a consensus target price of $34.36, indicating a potential upside of 25.91%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 165.39%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

ACADIA Pharmaceuticals beats Corvus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Celcuity?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Celcuity had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for Corvus Pharmaceuticals. Celcuity's average media sentiment score of 0.69 beat Corvus Pharmaceuticals' score of -0.07 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Celcuity	N/A	-350.78%	-41.54%

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 165.39%. Celcuity has a consensus price target of $154.75, indicating a potential upside of 91.97%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Corvus Pharmaceuticals beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Corvus Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.50 beat Corvus Pharmaceuticals' score of -0.07 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals' return on equity of -36.15% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 165.39%. Edgewise Therapeutics has a consensus target price of $50.33, suggesting a potential upside of 11.06%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Edgewise Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Dyne Therapeutics had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Dyne Therapeutics and 2 mentions for Corvus Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.27 beat Corvus Pharmaceuticals' score of -0.07 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics currently has a consensus target price of $32.17, suggesting a potential upside of 88.00%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 165.39%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Corvus Pharmaceuticals' return on equity of -36.15% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Summary

Dyne Therapeutics and Corvus Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Enliven Therapeutics and 2 mentions for Corvus Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 0.54 beat Corvus Pharmaceuticals' score of -0.07 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enliven Therapeutics presently has a consensus price target of $75.00, suggesting a potential upside of 51.67%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 165.39%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Enliven Therapeutics' return on equity of -18.55% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Summary

Corvus Pharmaceuticals beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.06B	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-20.59	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	99.08	108.90	76.25	51.42
Price / Book	17.21	15.45	10.46	6.33
Net Income	-$15.28M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-2.71%	-1.21%	0.59%	1.12%
1 Month Performance	-12.35%	-3.29%	-1.74%	-2.39%
1 Year Performance	113.97%	37.74%	18.13%	5.35%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	2.0645 of 5 stars	$12.56 +0.1%	$33.33 +165.4%	+114.0%	$1.06B	N/A	N/A	37	Analyst Forecast High Trading Volume
ACAD ACADIA Pharmaceuticals	4.4044 of 5 stars	$27.58 -1.6%	$34.36 +24.6%	+11.8%	$4.83B	$1.07B	12.42	510	Positive News
CELC Celcuity	2.9368 of 5 stars	$93.02 -2.8%	$154.55 +66.1%	+55.4%	$4.68B	N/A	N/A	40	News Coverage Analyst Forecast
EWTX Edgewise Therapeutics	2.2104 of 5 stars	$43.82 +1.7%	$50.33 +14.9%	+217.8%	$4.68B	N/A	N/A	60	News Coverage Positive News Options Volume
DYN Dyne Therapeutics	2.9488 of 5 stars	$20.31 -16.4%	$34.17 +68.2%	+30.3%	$4.53B	N/A	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. ACAD, CELC, EWTX, DYN, and ELVN

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. ACAD, CELC, EWTX, DYN, and ELVN

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Which has preferable valuation and earnings, ACAD or CRVS?

Does the media favor ACAD or CRVS?

Which has more volatility & risk, ACAD or CRVS?

Is ACAD or CRVS more profitable?

Do institutionals & insiders have more ownership in ACAD or CRVS?

Do analysts prefer ACAD or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Does the media refer more to CRVS or CELC?

Which has more risk and volatility, CRVS or CELC?

Which has preferable earnings and valuation, CRVS or CELC?

Do insiders & institutionals have more ownership in CRVS or CELC?

Is CRVS or CELC more profitable?

Do analysts recommend CRVS or CELC?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Does the media refer more to CRVS or EWTX?

Is CRVS or EWTX more profitable?

Which has preferable valuation & earnings, CRVS or EWTX?

Do institutionals & insiders hold more shares of CRVS or EWTX?

Do analysts prefer CRVS or EWTX?

Which has more risk & volatility, CRVS or EWTX?

Summary

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Does the media prefer DYN or CRVS?

Do analysts rate DYN or CRVS?

Which has better earnings & valuation, DYN or CRVS?

Which has more risk & volatility, DYN or CRVS?

Do institutionals and insiders hold more shares of DYN or CRVS?

Is DYN or CRVS more profitable?

Summary

How does Corvus Pharmaceuticals compare to Enliven Therapeutics?

Does the media prefer ELVN or CRVS?

Which has more volatility & risk, ELVN or CRVS?

Do insiders & institutionals hold more shares of ELVN or CRVS?

Do analysts prefer ELVN or CRVS?

Is ELVN or CRVS more profitable?

Which has preferable valuation and earnings, ELVN or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools